Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652092 · ClinicalTrials.gov registry record · NA
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
A NA study of Chronic Granulomatous Disease and Common Variable Immunodeficiency, sponsored by Masonic Cancer Center, University of Minnesota.
- Active
- Registry status
- NA
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT01652092 is a NA study of Chronic Granulomatous Disease and Common Variable Immunodeficiency that is active but no longer recruiting, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 57 participants, above the 27-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (111% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01652092, a NA study of Chronic Granulomatous Disease and Common Variable Immunodeficiency, is active but no longer recruiting, sponsored by Masonic Cancer Center, University of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Alemtuzumab 0.3 mg
- BIOLOGICAL Stem Cell Transplantation
- DRUG Fludarabine phosphate 40 mg
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2012-09-04 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01652092
The ClinicalTrials.gov registry entry for NCT01652092 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 27-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (111% higher). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Chronic Granulomatous Disease appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01652092 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01652092 about?
NCT01652092 is a clinical study titled "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies". This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
What is the current status of trial NCT01652092?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 57 participants. The study started on 2012-09-04. Estimated completion is 2026-12.
What conditions does trial NCT01652092 study?
This clinical trial studies the following conditions: Chronic Granulomatous Disease, Common Variable Immunodeficiency, Wiskott-Aldrich Syndrome, SCI/D, CD40 Ligand Deficiency.
What interventions are being tested in trial NCT01652092?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Alemtuzumab 0.3 mg (DRUG), Stem Cell Transplantation (BIOLOGICAL), Fludarabine phosphate 40 mg (DRUG).
Who is sponsoring clinical trial NCT01652092?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01652092 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Granulomatous Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
-
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
RECRUITING · Phase 1
-
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
ACTIVE NOT RECRUITING · Early Phase 1
-
Immune Disorder HSCT Protocol
ACTIVE NOT RECRUITING · Phase 2
-
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
ACTIVE NOT RECRUITING · Phase 1
-
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Chronic Granulomatous Disease
All registered trials for this condition
Common Variable Immunodeficiency
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.